Giancarlo Scognamiglio1, Aleksander Kempny2, Laura C Price3, Rafael Alonso-Gonzalez4, Philip Marino4, Lorna Swan4, Michele D' Alto5, James Hooper6, Michael A Gatzoulis4, Konstantinos Dimopoulos4, Stephen J Wort7. 1. Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK Department of Cardiology, Second University of Naples, Monaldi Hospital, Naples, Italy. 2. Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK Division of Adult Congenital and Valvular Heart Disease, Department of Cardiovascular Medicine, University Hospital Muenster, Muenster, Germany. 3. Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK National Heart and Lung Institute, Imperial College School of Medicine, London, UK. 4. Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK. 5. Department of Cardiology, Second University of Naples, Monaldi Hospital, Naples, Italy. 6. Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK. 7. Adult Congenital Heart Centre and National Centre for Pulmonary Hypertension, Royal Brompton Hospital, London, UK NIHR Cardiovascular Biomedical Research Unit, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College London, London, UK National Heart and Lung Institute, Imperial College School of Medicine, London, UK.
Abstract
OBJECTIVES: To assess the relationship of C-reactive protein (CRP) to clinical outcome and mortality in adults with pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD-PAH). BACKGROUND: Approximately 5-10% of adults with congenital heart disease (ACHD) develop PAH, which in turn is associated with substantial morbidity and mortality. Although CRP is known to predict outcome in idiopathic PAH, little is known regarding its prognostic value in CHD-PAH. METHODS: We obtained and analysed 1936 CRP values in a total of 225 adults with CHD-PAH (median age at study entry 34.0 years (27.0-41.7); 32.9% male, 35% with Down syndrome), performed over a 12-year period. High CRP values related to infection or blood transfusions were excluded from the analysis. RESULTS: During a median follow-up of 4.8 years (1149 patients-years), 50 patients died. The median CRP concentration on the last assessment was 5.0 mg/L (IQR 2.0-10.0), higher in deceased patients compared with survivors (11.5 mg/L (6.0-23.0) vs 4.0 mg/L (1.5-8.0), p<0.0001). Following univariate Cox regression analysis, CRP emerged as a strong predictor of mortality (HR 1.18; 95% CI 1.11 to 1.26, p<0.0001) and remained significant after adjustment for age, presence of Down syndrome and advanced PAH therapy. Survival-receiver-operator characteristic analysis identified an optimal cut-off value of 10 mg/L. Patients with CRP >10 mg/L had more than a threefold increased risk of death (HR 3.63, 95% CI 2.07 to 6.38, p<0.0001). CONCLUSIONS: Serum CRP is a simple but powerful marker of mortality in CHD-PAH patients and should be incorporated in the risk stratification and routine assessment of these patients. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVES: To assess the relationship of C-reactive protein (CRP) to clinical outcome and mortality in adults with pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD-PAH). BACKGROUND: Approximately 5-10% of adults with congenital heart disease (ACHD) develop PAH, which in turn is associated with substantial morbidity and mortality. Although CRP is known to predict outcome in idiopathic PAH, little is known regarding its prognostic value in CHD-PAH. METHODS: We obtained and analysed 1936 CRP values in a total of 225 adults with CHD-PAH (median age at study entry 34.0 years (27.0-41.7); 32.9% male, 35% with Down syndrome), performed over a 12-year period. High CRP values related to infection or blood transfusions were excluded from the analysis. RESULTS: During a median follow-up of 4.8 years (1149 patients-years), 50 patients died. The median CRP concentration on the last assessment was 5.0 mg/L (IQR 2.0-10.0), higher in deceased patients compared with survivors (11.5 mg/L (6.0-23.0) vs 4.0 mg/L (1.5-8.0), p<0.0001). Following univariate Cox regression analysis, CRP emerged as a strong predictor of mortality (HR 1.18; 95% CI 1.11 to 1.26, p<0.0001) and remained significant after adjustment for age, presence of Down syndrome and advanced PAH therapy. Survival-receiver-operator characteristic analysis identified an optimal cut-off value of 10 mg/L. Patients with CRP >10 mg/L had more than a threefold increased risk of death (HR 3.63, 95% CI 2.07 to 6.38, p<0.0001). CONCLUSIONS: Serum CRP is a simple but powerful marker of mortality in CHD-PAH patients and should be incorporated in the risk stratification and routine assessment of these patients. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Alexander R Opotowsky; Anne Marie Valente; Laith Alshawabkeh; Susan Cheng; Allison Bradley; Eric B Rimm; Michael J Landzberg Journal: Eur Heart J Date: 2018-09-07 Impact factor: 29.983
Authors: Matthew R Carazo; Meghan S Kolodziej; Elizabeth S DeWitt; Nadine A Kasparian; Jane W Newburger; Valeria E Duarte; Michael N Singh; Alexander R Opotowsky Journal: J Am Heart Assoc Date: 2020-04-28 Impact factor: 5.501
Authors: Laurie W Geenen; Vivan J M Baggen; Annemien E van den Bosch; Jannet A Eindhoven; Robert M Kauling; Judith A A E Cuypers; Jolien W Roos-Hesselink; Eric Boersma Journal: Heart Date: 2020-10-15 Impact factor: 5.994
Authors: Yang Zi-Yang; Zhao Kaixun; Luo Dongling; Yin Zhou; Zhou Chengbin; Chen Jimei; Zhang Caojin Journal: J Int Med Res Date: 2020-11 Impact factor: 1.671
Authors: Marta Banaszkiewicz; Aleksandra Gąsecka; Szymon Darocha; Michał Florczyk; Arkadiusz Pietrasik; Piotr Kędzierski; Michał Piłka; Adam Torbicki; Marcin Kurzyna Journal: J Clin Med Date: 2022-01-13 Impact factor: 4.241